Journal List > Korean J Gastroenterol > v.75(3) > 1144390

Chung, Min, Lee, Hong, Won, Jang, Kim, and Chang: Effects of Novel Probiotics in a Murine Model of Irritable Bowel Syndrome

Abstract

Background/Aims

Dysbiosis is an important factor in the pathogenesis of irritable bowel syndrome (IBS). Several studies have reported promising results using probiotics for the treatment of IBS. This study evaluated the efficacy of novel probiotics isolated from Kimchi, a Korean fermented food, and the feces of healthy Vietnamese people in a murine model of IBS.

Methods

Lactobacillus paracasei DK121 was isolated from Kimchi, and L. salivarius V4 and L. plantarum V7 were isolated from the feces of healthy Vietnamese people residing in Korea. Forty rats were allocated to receive one of the study strains, a mixture of the strains, or the vehicle. After 5 days of administration, the rats were restrained in a cage to induce IBS. The effects of the probiotics on IBS were analyzed by evaluating the stool weights and stool consistency scores.

Results

The primary outcome was analyzed upon the completion of a three-week experiment. The rats in the V7 group showed lower stool weights than those in the control group at week 2 (median: 1.10 [V7] vs. 2.35 [control], p=0.04, Mann-Whitney U-test) and week 3 (median: 1.10 [V7] vs. 2.80 [control], p=0.017). The rats in the DK121 (median: 2.00, p=0.007), V7 (median: 2.00, p=0.004), and mixture (median: 1.50, p=0.001) groups showed better stool consistency scores at week 2 than the control group (median: 3.00).

Conclusions

The novel probiotics have beneficial effects on defecation in a murine model of IBS. Human studies confirming the efficacy are warranted.

References

1. Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med. 2017; 376:2566–2578.
crossref
2. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015; 313:949–958.
3. Makharia GK, Verma AK, Amarchand R, et al. Prevalence of irritable bowel syndrome: a community based study from northern India. J Neurogastroenterol Motil. 2011; 17:82–87.
crossref
4. Quigley EMM. The gut-brain axis and the microbiome: clues to pathophysiology and opportunities for novel management strategies in irritable bowel syndrome (IBS). J Clin Med. 2018; 7:E6.
crossref
5. Pimentel M. Evidence-based management of irritable bowel syndrome with diarrhea. Am J Manag Care. 2018; 24(3 Suppl):S35–S46.
6. Principi N, Cozzali R, Farinelli E, Brusaferro A, Esposito S. Gut dysbiosis and irritable bowel syndrome: the potential role of probiotics. J Infect. 2018; 76:111–120.
crossref
7. Zhang Y, Li L, Guo C, et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016; 16:62.
crossref
8. Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol. 2013; 29:184–189.
crossref
9. Eutamene H, Lamine F, Chabo C, et al. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J Nutr. 2007; 137:1901–1907.
crossref
10. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010; 59:325–332.
crossref
11. Hungin AP, Mulligan C, Pot B, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice – an evidence-based international guide. Aliment Pharmacol Ther. 2013; 38:864–886.
crossref
12. Williams CL, Villar RG, Peterson JM, Burks TF. Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome. Gastroenterology. 1988; 94:611–621.
crossref
13. Gué M, Del Rio-Lacheze C, Eutamene H, Théodorou V, Fioramonti J, Buéno L. Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol Motil. 1997; 9:271–279.
crossref
14. Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: new therapeutic strategies. World J Gastroenterol. 2016; 22:2219–2241.
crossref
15. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014; 109(Suppl 1):S2–S26.
crossref
16. Stern EK, Brenner DM. Gut microbiota-based therapies for irritable bowel syndrome. Clin Transl Gastroenterol. 2018; 9:e134.
crossref
17. Zhuang X, Xiong L, Li L, Li M, Chen M. Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2017; 32:28–38.
crossref
18. Cho YH, Hong SM, Kim CH. Isolation and characterization of lactic acid bacteria from Kimchi, Korean traditional fermented food to apply into fermented dairy products. Korean J Food Sci An. 2013; 33:75–82.
crossref
19. Shin HS, Yoo SH, Jang JA, Won JY, Kim CH. Probiotic properties of lactic acid bacteria isolated from feces and Kimchi. J Milk Sci Biotechnol. 2017; 35:255–261.
20. Trentacosti AM, He R, Burke LB, Griebel D, Kennedy DL. Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. Am J Gastroenterol. 2010; 105:731–735.
crossref
21. Kobayashi S, Ikeda K, Suzuki M, Yamada T, Miyata K. Effects of YM905, a novel muscarinic M3-receptor antagonist, on ex-perimental models of bowel dysfunction in vivo. Jpn J Pharmacol. 2001; 86:281–288.
crossref
22. Dai C, Guandalini S, Zhao DH, Jiang M. Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: a possible action through nitric oxide pathway and enhance barrier function. Mol Cell Biochem. 2012; 362:43–53.
crossref
23. Miyata K, Ito H, Fukudo S. Involvement of the 5-HT3 receptor in CRH-induce defecation in rats. Am J Physiol. 1998; 274:G827–G831.
24. Traini C, Evangelista S, Girod V, Faussone-Pellegrini MS, Vannucchi MG. Changes of excitatory and inhibitory neuro-transmitters in the colon of rats underwent to the wrap partial re-straint stress. Neurogastroenterol Motil. 2016; 28:1172–1185.
crossref
25. Bashashati M, Moossavi S, Cremon C, et al. Colonic immune cells in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil. 2018; 30:e13192.
crossref
26. Bradesi S, Schwetz I, Ennes HS, et al. Repeated exposure to water avoidance stress in rats: a new model for sustained visceral hyperalgesia. Am J Physiol Gastrointest Liver Physiol. 2005; 289:G42–G53.
crossref
27. Barreau F, Salvador-Cartier C, Houdeau E, Bueno L, Fioramonti J. Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats. Gut. 2008; 57:582–590.
crossref
28. Lee JY, Kim N, Nam RH, et al. Probiotics reduce repeated water avoidance stress-induced colonic microinflammation in Wistar rats in a sex-specific manner. PLoS One. 2017; 12:e0188992.
crossref
29. Chen CC, Chow B, Sun Y, et al. Probiotic-mediated protection against chronic water-avoidance stress enteritis in mice is associated with lamina propria plasmacytoid dendritic cell infiltration. Gastroenterology. 2017; 152:S622.
crossref
30. Min YW, Rhee PL. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therap Adv Gastroenterol. 2015; 8:136–142.
crossref
31. Hungin APS, Mitchell CR, Whorwell P, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus. Aliment Pharmacol Ther. 2018; 47:1054–1070.
crossref
32. Pace F, Pace M, Quartarone G. Probiotics in digestive diseases: focus on Lactobacillus GG. Minerva Gastroenterol Dietol. 2015; 61:273–292.
33. Clarke G, Cryan JF, Dinan TG, Quigley EM. Review article: probiotics for the treatment of irritable bowel syndrome–focus on lactic acid bacteria. Aliment Pharmacol Ther. 2012; 35:403–413.

Fig. 1.
Study design.
kjg-75-141f1.tif
Fig. 2.
Cylindrical cage used to confine the rats during the experiment (diameter, 70 mm; height, 220 mm). Each rat was restrained in this cage for 1 hour on days 6, 13, and 20, provoking stress-induced defecation.
kjg-75-141f2.tif
Fig. 3.
Body weights of rats during the 3-week study period. Each dot represents the median body weight (g) of the rats in the assigned group.
kjg-75-141f3.tif
Fig. 4.
Stool weights of the rats in each study group during the 3 weeks of probiotics administration. The rats in the V7 group had lower stool weights than those in the control group at weeks 2 (p=0.040) and 3 (p=0.017). The rats in the DK121 group had lower stool weights than the control group at week 3 with marginal statistical significance (p=0.073). The lines are the median and interquartile range of the eight animals in each group. Each value is shown as a scatter dot. Lines and scatter dots are shown for the control, DK121, V4, V7, and the mixture groups.
kjg-75-141f4.tif
Fig. 5.
Stool consistency scores of the rats in each study group during the 3-week probiotics treatment experiment. The rats in the DK121(p=0.007), V7 (p=0.004), and the mixture (p=0.001) groups showed better (lower) stool consistency scores than the control group at week 2. No significant difference was observed among the study groups at week 3. The lines represent the median and interquartile range of the eight animals in each group. Each value is shown as a scatter dot. The lines and scatter dots are shown for the control, DK121, V4, V7, and the mixture groups.
kjg-75-141f5.tif
TOOLS
ORCID iDs

Yang Won Min
https://orcid.org/0000-0001-7471-1305

Similar articles